Clinical Trials

Several completed Phase 2 and Phase 3 clinical trials, all sponsored by Sirion Therapeutics Inc., have evaluated the therapeutic application of difluprednate. These studies focused primarily on assessing the safety and efficacy of difluprednate in managing inflammatory conditions, particularly postoperative inflammation following cataract surgery. Together, this clinical evidence supports the utility of difluprednate for reducing inflammation in clinical settings.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00616993 Completed
Inflammation
Sirion Therapeutics Inc.
 2008-01 Phase 3
NCT00616070 Completed
Inflammation
Sirion Therapeutics Inc.
 2007-12 Phase 3
NCT00407225 Completed
Inflammation
Sirion Therapeutics Inc.
 1999-12 Phase 2
NCT00430092 Completed
Inflammation
Sirion Therapeutics Inc.
 Phase 3
NCT00429923 Completed
Inflammation
Sirion Therapeutics Inc.
 Phase 3

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Difluprednate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Difluprednate acts as a synthetic agonist that binds to glucocorticoid receptors, thereby inhibiting NF-κB activation and downregulating the transcription of pro-inflammatory cytokines and enzymes. This suppression reduces vascular permeability and inflammatory cell infiltration, providing the mechanistic basis for its therapeutic efficacy in treating inflammatory conditions in clinical trials.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.